Research programme: scar, wound and fibrosis therapeutics - Symic Bio

Drug Profile

Research programme: scar, wound and fibrosis therapeutics - Symic Bio

Alternative Names: SBR-294

Latest Information Update: 17 Apr 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator SYMIC Biomedical
  • Developer Symic Bio
  • Class Antifibrotics; Eye disorder therapies; Skin disorder therapies
  • Mechanism of Action Inflammation mediator modulators; Platelet activating factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Fibrosis; Hepatic fibrosis; Scars; Wounds
  • Research Corneal injuries

Most Recent Events

  • 16 Apr 2018 Symic Bio announces intention to submit IND application for SBR 294 for Hepatic fibrosis in 2019
  • 16 Apr 2018 Pharmacodynamics data from preclinical studies in Hepatic fibrosis presented at the The International Liver Congress (ILC-2018)
  • 05 Jan 2015 Early research in Corneal injuries (scarring) in USA (Intralesional)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top